Emergent BioSolutions (EBS) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $5.90 -5.6%
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Selling, general and administrative: 40.69M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q3 EPS of $2.19, $0.07 better than the analyst estimate of $2.12. Revenue for the quarter came in at $385.2 million versus the consensus estimate of $437.93 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Stabilis Solutions, Inc. (SLNG) Tops Q3 EPS by 3c
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
